Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.
Menu

Enliven Therapeutics Inc (ELVN)

Enliven Therapeutics Inc (ELVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch Watch
Help
Go To:
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting PR Newswire - Mon Aug 31, 5:05PM CDT

BURLINGAME, Calif. , Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development...

ELVN : 58.38 (+0.90%)
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares PR Newswire - Mon Jun 15, 3:40PM CDT

BURLINGAME, Calif. , June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development...

ELVN : 58.38 (+0.90%)
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire - Thu Jun 11, 9:39PM CDT

BURLINGAME, Calif. , June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development...

ELVN : 58.38 (+0.90%)
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire - Thu Jun 11, 3:05PM CDT

BURLINGAME, Calif. , June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development...

ELVN : 58.38 (+0.90%)
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components PR Newswire - Thu Jun 11, 7:00AM CDT

61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort

ELVN : 58.38 (+0.90%)
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress PR Newswire - Wed Jun 3, 3:05PM CDT

Enliven will host a   webcast conference call   on   June   11,   at   8:30   a.m.   ET

ELVN : 58.38 (+0.90%)
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML PR Newswire - Tue May 12, 8:53AM CDT

Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort

ELVN : 58.38 (+0.90%)
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update PR Newswire - Thu May 7, 3:05PM CDT

Phase 1 data update for ELVN-001 expected mid-2026

ELVN : 58.38 (+0.90%)
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference PR Newswire - Wed Feb 25, 3:05PM CST

BOULDER, Colo. , Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development...

ELVN : 58.38 (+0.90%)
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones PR Newswire - Thu Jan 8, 8:00AM CST

Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts

ELVN : 58.38 (+0.90%)

Barchart Exclusives

Plains All American Stock Is a Top Pick for Growth and Income Barchart - 9 minutes ago
Plains All American Pipeline (PAA) demonstrates strong technical momentum, with shares up more than 45% over the past year. The stock is trading at a new 5-year high. PAA boasts a 6.54% dividend yield, which adds to its appeal. PAA’s crude oil and NGL segments are positioned for volume-driven growth,... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.